autologous blood and marrow transplantation - Blog Science ...

Table 1. Continued
Santini et al. 195
Arm A (n-- =61) ArmB (n-=63)
Characteristic n % n %
Immunophenotype
B 46 75 52 83
T 8 13 6 9
Null 7 12 5 8
Stage
II 18 29 22 35
III 12 20 13 21
IV 31 51 28 44
Symptoms
A 36 59 30 48
B 25 41 33 52
Extranodal sites
0 33 54 37 59
1 13 21 11 17
>2 15 25 15 24
Bulky disease
No 31 51 22 35
Yes 30 49 41 65
Lactate dehydrogenase
NV 27 44 23 36
>1 NV 23 38 25 40
>2NV 11 18 15 24
International Index
Low 8 13 6 10
Low-intermediate 17 28 23 36
Intermediate-high 27 44 27 43
High 9 15 7 11
Ineligible patients 1 2 2 3
After pretreatment evaluation, 124 patients were randomly assigned to receive
either VACOP-B 15
(arm A, 61 patients) for 12 weeks or the same regimen followed
by autoBMT as described 14
(arm B, 63 patients).
Arm A patients who obtained a complete remission underwent follow-up.
Patients in PR, nonresponders (NR), or relapsed patients underwent salvage
DHAP 16
regimen with or without involved-field radiotherapy on residual masses.
Arm B patients were to proceed to autoBMT independently of disease status (CR,
PR, or NR) at the end of VACOP-B. On completion of treatment, patients with
residual masses received involved-field radiotherapy. Relapsed patients were to be
treated with DHAP regimen with or without radiotherapy.